Comparing Carboplatin and Ifosfamide/Carboplatin for Ovarian Cancer
Author Information
Author(s): T.J. Perren, E. Wiltshaw, P. Harper, M. Slevin, R. Stein, S. Tan, M. Gore, I.J. Fryatt, P.R. Blake
Primary Institution: The Royal Marsden Hospital
Hypothesis
Is sequential therapy with ifosfamide followed by carboplatin more effective than carboplatin alone for patients with FIGO stage III epithelial ovarian carcinoma?
Conclusion
Ifosfamide is less effective and more toxic than carboplatin, but can be salvaged by subsequent carboplatin treatment.
Supporting Evidence
- 29% response rate for ifosfamide compared to 63% for carboplatin after three cycles.
- 47% of patients in the ifosfamide/carboplatin arm developed significant alopecia.
- Median survival was 21.5 months for carboplatin and 18.7 months for ifosfamide/carboplatin.
Takeaway
This study looked at two treatments for ovarian cancer and found that one treatment worked better and was safer than the other.
Methodology
Patients were randomized to receive either sequential therapy with ifosfamide followed by carboplatin or six cycles of carboplatin alone.
Limitations
The study is relatively small and may not have enough power to detect significant differences in survival.
Participant Demographics
Patients with FIGO stage III ovarian carcinoma who had received no previous chemotherapy or radiotherapy.
Statistical Information
P-Value
0.0008
Confidence Interval
95% CI: 49-76% for carboplatin, 95% CI: 17-43% for ifosfamide/carboplatin
Statistical Significance
p=0.0008
Want to read the original?
Access the complete publication on the publisher's website